Physician profile
John Williams
NPI 1215548656
$4,146.59
in general payments reported to CMS, 2019-2025
20 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $410 · 2022: $1,132 · 2023: $521 · 2024: $936 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Travel and Lodging: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.96 |
| Travel and Lodging | $461.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.34 | 2021-2024 | |
| Nevro Corp. | $693.55 | 2021-2024 | Senza |
| Boston Scientific Corporation | $653.44 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Mml US, INC. | $581.20 | 2025 | Reactiv8 |
| Allergan, INC. | $221.24 | 2021-2022 | |
| Saluda Medical Americas, INC. | $189.28 | 2024 | Evoke |
| Biohaven Pharmaceutical Holding Company Ltd. | $169.43 | 2022 | |
| Globus Medical, INC. | $167.96 | 2025 | Senza, Vyrsa V1 |
| Scilex Pharmaceuticals INC. | $106.09 | 2021-2023 | Ztlido |
| Medtronic, INC. | $97.42 | 2022-2023 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $94.52 | 2023 | Belbuca, Xtampza |
| Biohaven Pharmaceuticals, INC. | $78.92 | 2021 | |
| Biodelivery Sciences International, INC. | $48.91 | 2021 | |
| Pfizer INC. | $39.86 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $39.78 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $31.95 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $25.99 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.55 | 2025 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.76 | 2024 | Relistor |
| Ibsa Pharma INC. | $16.40 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.